Yvonne McGrath - Mar 9, 2023 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Scientific Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Mar 9, 2023
Transactions value $
$0
Form type
4
Date filed
3/10/2023, 06:54 PM
Previous filing
Mar 14, 2022
Next filing
Dec 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +130K $0.00 130K Mar 9, 2023 Common Stock 130K $16.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.